尼拉帕利在65岁及以上晚期卵巢癌患者中的疗效与安全性:PRIMA/ENGOT-OV26/GOG-3012试验结果
该研究为PRIMA/ENGOT-OV26/GOG-3012三期试验的事后分析,评估年龄对尼拉帕利一线维持治疗新诊断晚期卵巢癌疗效与安全性的影响。733例随机患者中289例(39.4%)≥65岁,两个年龄亚组的中位无进展生存期和风险比相似,但≥65岁患者因治疗中出现的不良事件导致停药的比例更高。采用个体化起始剂量可降低两个年龄亚组中≥3级血小板减少症的发生率。
要点
- 尼拉帕利一线维持治疗在<65岁和≥65岁患者中疗效相似,中位无进展生存期分别为13.9个月和13.7个月。
- ≥65岁患者因治疗中出现的不良事件导致停药的比例为18.4%,高于<65岁患者的7.8%。
- 采用个体化起始剂量可降低≥3级血小板减少症发生率,<65岁为18.0%对比42.8%,≥65岁为26.1%对比57.0%。
核心结论
- 尼拉帕利的疗效、安全性和健康相关生活质量在各年龄亚组间总体相当,但≥65岁患者因治疗中出现的不良事件导致停药的比例更高。
- 采用个体化起始剂量可降低≥3级血小板减少症事件的发生率,且与年龄无关。
研究设计与样本
- PRIMA/ENGOT-OV26/GOG-3012研究(NCT02655016)的事后分析,该研究为三期试验。
- 意向治疗人群按基线年龄分为<65岁和≥65岁亚组,评估无进展生存期、安全性和健康相关生活质量,临床截止日期为2019年5月17日。
- 安全性结果还按固定起始剂量或个体化起始剂量进行评估。
- 733例随机患者中,289例(39.4%)基线时≥65岁(尼拉帕利组190例,安慰剂组99例)。
主要发现
- 中位无进展生存期(尼拉帕利对比安慰剂)和风险比(95% CI)在<65岁患者中为13.9个月对比8.2个月,HR为0.61(0.47-0.81);在≥65岁患者中为13.7个月对比8.1个月,HR为0.53(0.39-0.74)。
- 任何级别和≥3级治疗中出现的不良事件发生率在各年龄亚组间相似。
- 在尼拉帕利组中,导致剂量中断的治疗中出现的不良事件在<65岁患者中发生率为7.8%,在≥65岁患者中为18.4%。
- 与固定起始剂量相比,个体化起始剂量降低了尼拉帕利治疗患者中≥3级血小板减少症事件的发生率(<65岁:42.8%对比18.0%;≥65岁:57.0%对比26.1%)。
- 健康相关生活质量在各年龄亚组间相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of age on the efficacy and safety of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer with a complete/partial response to first-line platinum-based chemotherapy. METHODS: Post hoc analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016). Patients in the intent-to-treat population were categorized according to age at baseline (<65 years vs ≥65 years), and progression-free survival (PFS), safety, and health-related quality of life (HRQOL) were evaluated for each age subgroup (clinical cutoff date, May 17, 2019). Safety findings were also evaluated according to a fixed starting dose (FSD) or an individualized starting dose (ISD). RESULTS: Of 733 randomized patients, 289 (39.4%) were ≥65 years (190 niraparib, 99 placebo) at baseline. Median PFS (niraparib vs placebo) and hazard ratios (95% CI) were similar in patients aged <65 years (13.9 vs 8.2 months; HR, 0.61 [0.47-0.81]) and ≥65 years (13.7 vs 8.1 months; HR, 0.53 [0.39-0.74]). The incidences of any-grade and grade ≥3 treatment-emergent adverse events (TEAEs) were similar across age subgroups; in the niraparib arm, TEAEs leading to dose discontinuation occurred in 7.8% of patients <65 years and 18.4% of patients ≥65 years. ISD use lowered the incidence of grade ≥3 thrombocytopenia events in niraparib-treated patients compared with the FSD (<65 years: 42.8% vs 18.0%; ≥65 years 57.0% vs 26.1%). HRQOL was comparable across age subgroups. CONCLUSION: Niraparib efficacy, safety, and HRQOL were generally comparable across age subgroups, although patients ≥65 years had a higher rate of discontinuations due to TEAEs. ISD use reduced grade ≥3 thrombocytopenia events regardless of age.
引用
- Valabrega G, Pothuri B, Oaknin A, et al. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024. PMID: 38833992. doi:10.1016/j.ygyno.2024.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。